FI870457A0 - PHARMACEUTICAL FORM FOR STABILIZATION OF THE INTERFERENCE. - Google Patents

PHARMACEUTICAL FORM FOR STABILIZATION OF THE INTERFERENCE.

Info

Publication number
FI870457A0
FI870457A0 FI870457A FI870457A FI870457A0 FI 870457 A0 FI870457 A0 FI 870457A0 FI 870457 A FI870457 A FI 870457A FI 870457 A FI870457 A FI 870457A FI 870457 A0 FI870457 A0 FI 870457A0
Authority
FI
Finland
Prior art keywords
active ingredient
stabilization
interference
pharmaceutical form
ifn alpha
Prior art date
Application number
FI870457A
Other languages
Finnish (fi)
Other versions
FI870457A (en
FI86144C (en
FI86144B (en
Inventor
Helmut Franz
Original Assignee
Thomae Gmbh Dr K
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thomae Gmbh Dr K filed Critical Thomae Gmbh Dr K
Publication of FI870457A0 publication Critical patent/FI870457A0/en
Publication of FI870457A publication Critical patent/FI870457A/en
Application granted granted Critical
Publication of FI86144B publication Critical patent/FI86144B/en
Publication of FI86144C publication Critical patent/FI86144C/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

The pharmaceutical forms are intended for topical administration and employ as vehicle for and stabiliser of the active ingredient a composition which specifically confers special stability on the active ingredient IFN alpha. The forms are essentially composed of hydroxyethylcellulose and gelatin and preferably contain highly purified IFN alpha which has been prepared by DNA recombination as active ingredient.
FI870457A 1986-02-05 1987-02-03 FOERFARANDE FOER FRAMSTAELLNING AV PHARMACEUTICAL PREPARATFORMER FOER TOPISK ANVAENDNING FOER STABILIZERING AV -INTERFERON. FI86144C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19863603444 DE3603444A1 (en) 1986-02-05 1986-02-05 PHARMACEUTICAL PREPARATIONS FOR STABILIZING INTERFERON ALPHA
DE3603444 1986-02-05

Publications (4)

Publication Number Publication Date
FI870457A0 true FI870457A0 (en) 1987-02-03
FI870457A FI870457A (en) 1987-08-06
FI86144B FI86144B (en) 1992-04-15
FI86144C FI86144C (en) 1992-07-27

Family

ID=6293372

Family Applications (1)

Application Number Title Priority Date Filing Date
FI870457A FI86144C (en) 1986-02-05 1987-02-03 FOERFARANDE FOER FRAMSTAELLNING AV PHARMACEUTICAL PREPARATFORMER FOER TOPISK ANVAENDNING FOER STABILIZERING AV -INTERFERON.

Country Status (20)

Country Link
EP (1) EP0231816B1 (en)
JP (1) JPS62209024A (en)
KR (1) KR870007698A (en)
AT (1) ATE63823T1 (en)
AU (1) AU601712B2 (en)
CA (1) CA1295242C (en)
DD (1) DD284602A5 (en)
DE (2) DE3603444A1 (en)
DK (1) DK164202C (en)
ES (1) ES2028796T3 (en)
FI (1) FI86144C (en)
GR (1) GR3002270T3 (en)
HU (1) HU196560B (en)
IE (1) IE59697B1 (en)
IL (1) IL81472A0 (en)
NO (1) NO169638C (en)
NZ (1) NZ219169A (en)
PH (1) PH24377A (en)
PT (1) PT84243B (en)
ZA (1) ZA87793B (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5275804A (en) * 1986-02-25 1994-01-04 E. B. Michaels Research Associates, Inc. Process and composition for oral hygiene
US5266310A (en) * 1987-09-17 1993-11-30 Boehringer Ingelheim International Gmbh Stabilization of therapeutically active proteins in pharmaceutical preparations
DE3731255A1 (en) * 1987-09-17 1989-04-06 Boehringer Ingelheim Int Stabilization of therapeutically active proteins in pharmaceutical preparations
DE3803312A1 (en) * 1988-02-04 1989-08-10 Gerd Prof Dr Med Gross Use of an interferon-containing gel
NO179479C (en) * 1988-03-11 1996-10-16 Teikoku Seiyaku Kk Process for the preparation of an intravaginal pharmaceutical preparation
ATE110571T1 (en) * 1988-05-06 1994-09-15 Toray Industries STABLE INTERFERON BETA COMPOSITION.
US5389676A (en) * 1991-03-22 1995-02-14 E. B. Michaels Research Associates, Inc. Viscous surfactant emulsion compositions
US5244652A (en) * 1991-03-22 1993-09-14 E. B. Michaels Research Associates, Inc. Viscous surface active composition
US5863530A (en) * 1991-10-11 1999-01-26 Spruson & Ferguson Treating ophthalmic fibrosis using interferon-α
CA2120950A1 (en) * 1991-10-11 1993-04-15 Mark C. Gillies Treating ophthalmic fibrosis using interferon-alpha
US6630168B1 (en) * 1997-02-20 2003-10-07 Biomedicines, Inc. Gel delivery vehicles for anticellular proliferative agents
FI106465B (en) * 1998-06-10 2001-02-15 Suomen Punainen Risti Veripalv A process for preparing virus-safe pharmaceutical compositions
US6923966B2 (en) 1999-04-08 2005-08-02 Schering Corporation Melanoma therapy
JP4536194B2 (en) * 2000-02-17 2010-09-01 大日本住友製薬株式会社 Stable injectable formulation
CN100488517C (en) * 2000-03-07 2009-05-20 拉什-长老会-圣路加医学中心 Composition for trapping and inactivating pathogenic microbes and spermatozoa and its pharmaceutical uses
US6328987B1 (en) * 2000-11-03 2001-12-11 Jan Marini Skin Research, Inc. Cosmetic skin care compositions containing alpha interferon
CA2464889A1 (en) * 2001-11-02 2003-05-08 Sekisui Chemical Co., Ltd. Cytokine-inducing material and cytokine-inducing instrument
US8137677B2 (en) * 2005-10-06 2012-03-20 Allergan, Inc. Non-protein stabilized clostridial toxin pharmaceutical compositions
KR101673044B1 (en) * 2009-05-29 2016-11-04 이노닉스 테크놀로지스, 인코포레이티드 Composition for use in decreasing the transmission of human pathogens
CA2866115C (en) 2012-03-01 2020-03-24 Firststring Research, Inc. Topical gels containing alpha connexin c-terminal (act) peptides
JP6081156B2 (en) * 2012-11-15 2017-02-15 アルケア株式会社 Hydrogel
DE102012222365A1 (en) 2012-12-05 2014-06-05 Aesculap Ag Composition for use in the prophylaxis of post-surgical adhesions
CA2913115A1 (en) * 2013-06-09 2014-12-18 Efranat Ltd. Compositions comprising gc-macrophage activating factor and uses thereof
WO2018143911A1 (en) 2017-01-31 2018-08-09 Kimberly-Clark Worldwide, Inc. Antibacterial composition including benzoic acid ester and methods of inhibiting bacterial growth utilizing the same

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1234383A (en) * 1982-03-17 1983-09-22 Inter-Yeda Ltd. Interferon stabilised with polyvinyl-pyrrolidone
JPS6061535A (en) * 1983-08-24 1985-04-09 エフ・ホフマン・ラ・ロシユ・ウント・コンパニ−・アクチエンゲゼルシヤフト Pharmaceutical composition
JPS6069037A (en) * 1983-09-26 1985-04-19 Sunstar Inc External preparation for erythematosus
DE3484951D1 (en) * 1983-10-14 1991-09-26 Sumitomo Pharma EXTENDED PREPARATIONS WITH DELAYED DELIVERY.
US4680175A (en) * 1984-02-07 1987-07-14 Interferon Sciences, Inc. Interferon administration vehicles
CA1248450A (en) * 1984-04-05 1989-01-10 Kazuo Kigasawa Soft patch
JPS60228422A (en) * 1984-04-26 1985-11-13 Suntory Ltd Stabilized preparation of physiologically active substance
JPS60260523A (en) * 1984-06-07 1985-12-23 Asahi Chem Ind Co Ltd Lyophilized drug composition of interferon

Also Published As

Publication number Publication date
DE3603444A1 (en) 1987-08-06
NO169638B (en) 1992-04-13
HU196560B (en) 1988-12-28
DE3770280D1 (en) 1991-07-04
DD284602A5 (en) 1990-11-21
FI870457A (en) 1987-08-06
EP0231816A3 (en) 1987-09-23
PT84243A (en) 1987-03-01
AU601712B2 (en) 1990-09-20
NO870441L (en) 1987-08-06
DK164202B (en) 1992-05-25
HUT43494A (en) 1987-11-30
FI86144C (en) 1992-07-27
ES2028796T3 (en) 1992-07-16
IL81472A0 (en) 1987-09-16
EP0231816A2 (en) 1987-08-12
GR3002270T3 (en) 1992-12-30
EP0231816B1 (en) 1991-05-29
IE870295L (en) 1987-08-05
KR870007698A (en) 1987-09-21
PT84243B (en) 1989-09-14
ZA87793B (en) 1988-10-26
DK58387D0 (en) 1987-02-04
CA1295242C (en) 1992-02-04
DK164202C (en) 1992-10-19
IE59697B1 (en) 1994-03-23
JPS62209024A (en) 1987-09-14
AU6829287A (en) 1987-08-06
DK58387A (en) 1987-08-06
PH24377A (en) 1990-06-13
ATE63823T1 (en) 1991-06-15
NO169638C (en) 1992-07-22
NO870441D0 (en) 1987-02-04
FI86144B (en) 1992-04-15
NZ219169A (en) 1990-04-26

Similar Documents

Publication Publication Date Title
FI870457A0 (en) PHARMACEUTICAL FORM FOR STABILIZATION OF THE INTERFERENCE.
DE3581819D1 (en) PYRIDAZINE AMINS EFFECTIVE AGAINST VIRUSES.
FI871750A0 (en) NASAL ADMINISTRATION AV CEILINGS MODEL.
ATE188119T1 (en) REMEDIES FOR WOUNDS AND HEMORRHOIDS
IE781032L (en) Pharmaceutical compositions
NO165071C (en) ANALOGUE PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE 7- (3-AMINO-1-PYRROLIDINYL) -8-CHLORO-1-CYCLOPROPYL-6-FLUORO-1,4, -DIHYDRO-4-OXO-3-CHINOLINE-CARBOXYL.
AU1518492A (en) Pharmaceutical compositions for transcutaneous administration
GB2021409A (en) Pharmaceutical composition
IT8620208A0 (en) SUBSTITUTED 7-OXABICICHLOHEPTANETHERS AS PROSTAGLANDIN ANALOGUES AND RELATED PHARMACEUTICAL COMPOSITIONS.
FR2691149B1 (en) NOVEL THIOCHROMANIC COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
AU581856B2 (en) 1-(4'-alkylthiophenyl)-2-amino-1, 3-propanediol N-substituted derivatives
FR2694005B1 (en) New aminoalkylchromones, methods for their preparation and pharmaceutical compositions containing them.
FI894813A (en) Process for the preparation of therapeutically active 2-methoxycarbonyl-substituted N, N'-di (trimethoxybenzoyl) piperazine derivatives
EP0355899A3 (en) Nucleotide derivatives
DK0578535T3 (en) New peptide derivatives active in cell adhesion processes, processes for their preparation, and pharmaceutical compositions containing the derivatives
IT8125874A0 (en) THERAPEUTIC COMPOSITIONS WITH CHOLERETIC ADAPTIVITY CONTAINING DERIVED FROM CHOLANIC ACID AS THE ACTIVE INGREDIENT.
NO863005D0 (en) PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE 1,4,5,6,7,8-HEXSAHYDRO-2-ALKYL-4-ARYL-5-OXO-1,7-NAFTYRIDINE-3-CARBOXYL ACID ESTER DERIVATIVES.
FR2691967B1 (en) NOVEL PYRROLOTHIENOPYRAZINIC COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
KR860002498A (en) Pharmaceutical Compositions of 1,4-Dihydropyridine Derivatives
FR2567755B1 (en) NEW ANTI-TUMOR DRUG CONTAINING TRIACETOXY-1,8,9 ANTHRACENE AS ACTIVE INGREDIENT
IT8819541A0 (en) PHARMACEUTICAL COMPOSITION FOR NASAL ADMINISTRATION.

Legal Events

Date Code Title Description
MM Patent lapsed
MM Patent lapsed

Owner name: DR. KARL THOMAE GESELLSCHAFT MIT